Global Autoinjectors Market to Reach Worth USD 2.7 Bn by 2022: Credence Research
According to the latest report published by Credence Research, Inc. “Global Autoinjectors Market (Manual Injection Autoinjectors, Automated Injection Autoinjectors, Reusable Autoinjectors, Disposable Autoinjectors, Variable Dose Autoinjectors & Smart Autoinjectors; & Therapeutic Areas) - Growth, Future Prospects and Competitive Assessment, 2016 - 2022,” the autoinjectors market was valued at USD 869.0 Mn in 2015, and is expected to reach USD 2,740.7 Mn by 2022, expanding at a CAGR of 18% from 2016 to 2022. Browse the full report Global Autoinjectors Market - Growth, Opportunities, Competitive Analysis, and Forecast, 2016 – 2022 report at http://www.credenceresearch.com/report/autoinjectors-market
According to the latest report published by Credence Research, Inc. “Global Autoinjectors Market (Manual Injection Autoinjectors, Automated Injection Autoinjectors, Reusable Autoinjectors, Disposable Autoinjectors, Variable Dose Autoinjectors & Smart Autoinjectors; & Therapeutic Areas) - Growth, Future Prospects and Competitive Assessment, 2016 - 2022,” the autoinjectors market was valued at USD 869.0 Mn in 2015, and is expected to reach USD 2,740.7 Mn by 2022, expanding at a CAGR of 18% from 2016 to 2022.
Browse the full report Global Autoinjectors Market - Growth, Opportunities, Competitive Analysis, and Forecast, 2016 – 2022 report at http://www.credenceresearch.com/report/autoinjectors-market
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>Global</strong> <strong>Au<strong>to</strong>injec<strong>to</strong>rs</strong> <strong>Market</strong> <strong>to</strong> <strong>Reach</strong> <strong>Worth</strong> <strong>USD</strong> <strong>2.7</strong> <strong>Bn</strong> <strong>by</strong><br />
<strong>2022</strong>: <strong>Credence</strong> <strong>Research</strong><br />
According <strong>to</strong> the latest report published <strong>by</strong> <strong>Credence</strong> <strong>Research</strong>, Inc. “<strong>Global</strong> <strong>Au<strong>to</strong>injec<strong>to</strong>rs</strong> <strong>Market</strong><br />
(Manual Injection <strong>Au<strong>to</strong>injec<strong>to</strong>rs</strong>, Au<strong>to</strong>mated Injection <strong>Au<strong>to</strong>injec<strong>to</strong>rs</strong>, Reusable <strong>Au<strong>to</strong>injec<strong>to</strong>rs</strong>, Disposable<br />
<strong>Au<strong>to</strong>injec<strong>to</strong>rs</strong>, Variable Dose <strong>Au<strong>to</strong>injec<strong>to</strong>rs</strong> & Smart <strong>Au<strong>to</strong>injec<strong>to</strong>rs</strong>; & Therapeutic Areas) - Growth, Future<br />
Prospects and Competitive Assessment, 2016 - <strong>2022</strong>,” the au<strong>to</strong>injec<strong>to</strong>rs market was valued at <strong>USD</strong> 869.0<br />
Mn in 2015, and is expected <strong>to</strong> reach <strong>USD</strong> 2,740.7 Mn <strong>by</strong> <strong>2022</strong>, expanding at a CAGR of 18% from 2016 <strong>to</strong><br />
<strong>2022</strong>.<br />
Browse the full report <strong>Global</strong> <strong>Au<strong>to</strong>injec<strong>to</strong>rs</strong> <strong>Market</strong> - Growth, Opportunities, Competitive Analysis, and<br />
Forecast, 2016 – <strong>2022</strong> report at http://www.credenceresearch.com/report/au<strong>to</strong>injec<strong>to</strong>rs-market<br />
<strong>Market</strong> Insights<br />
The global au<strong>to</strong>injec<strong>to</strong>rs market is anticipated <strong>to</strong> undergo swift progress during the forecast period. This<br />
market is characterized <strong>by</strong> rapid technological developments, growing count of severe allergy patients<br />
and growing awareness about self-administered prefilled injections. The demand for disposable<br />
au<strong>to</strong>injec<strong>to</strong>rs will grow significantly during the forecast period.<br />
Due <strong>to</strong> corresponding demands from drug administration industry, the biopharmaceutical companies<br />
worldwide have introduced several solutions for injectable drug delivery and are perpetually pushing for<br />
improvements in design and mechanism. It is expected that a significant part of new treatment<br />
introductions in the market will comprise of injectables, out of which au<strong>to</strong>injec<strong>to</strong>rs is the fastest emerging<br />
drug delivery solutions, since these products deliver better patient experience and treatment adherence<br />
through safe self-administration at home. Apart from the offered patient benefits, reduction in the<br />
number of hospital visits can ultimately assist in reducing cost of healthcare and contain the burden on<br />
healthcare personnel. New ergonomic designs and mechanisms introduced in au<strong>to</strong>injec<strong>to</strong>rs have also<br />
helped <strong>to</strong> efficiently address patient dexterity issues and minimize the risk of needle-stick injuries.<br />
Browse All Reports of This Category @ http://www.credenceresearch.com/industry/medical-devicesmarket<br />
<strong>Au<strong>to</strong>injec<strong>to</strong>rs</strong> are being increasingly considered <strong>by</strong> biopharmaceutical companies as an appropriate<br />
solution <strong>to</strong> commercialize their therapeutic solutions. However for successful commercialization and<br />
implementation of related strategies, the companies require detailed planning, thorough knowledge of<br />
drug-device combination mechanism, regula<strong>to</strong>ry requirements and synergy with device manufacturers.
Acting against this, biopharmaceutical companies and device manufacturers have varied product<br />
lifecycles and thus product development process may lead <strong>to</strong> gaps that might be crucial for the overall<br />
project and affect commercialization and profitability. It is hence crucial for biopharmaceutical companies<br />
<strong>to</strong> have in-depth understanding of every intermediate stage, the stage of entry of device manufacturer,<br />
meeting regula<strong>to</strong>ry mandates and other such processes.<br />
Request free sample - http://www.credenceresearch.com/sample-request/58015<br />
This market is intensely competitive, yet a handful of players take over significant market shares.<br />
Upcoming introductions of several au<strong>to</strong>injec<strong>to</strong>r products in 2018 and future will bring significant<br />
movements in the overall au<strong>to</strong>injec<strong>to</strong>rs market. Some of the key players operating in development,<br />
manufacture and sale of au<strong>to</strong>injec<strong>to</strong>rs in the international markets are Biogen Idec, Inc., Bec<strong>to</strong>n, Dickinson<br />
and Company, Antares Pharma, Inc., Mylan, Inc., Novartis International AG, Unilife Corporation, Pfizer,<br />
Inc., Scandinavian Health Ltd., Ypsomed Holding AG, Sanofi S. A., Bayer AG, Emergent BioSolutions and<br />
others.<br />
About Us:<br />
<strong>Credence</strong> <strong>Research</strong> is a worldwide market research and counseling firm that serves driving organizations,<br />
governments, non-legislative associations, and not-for-benefits. We offer our cus<strong>to</strong>mers some assistance<br />
with making enduring enhancements <strong>to</strong> their execution and understand their most imperative objectives.<br />
Over almost a century, we’ve manufactured a firm extraordinarily prepared <strong>to</strong> this task.<br />
Who we are<br />
<strong>Credence</strong> <strong>Research</strong> is a worldwide firm, containing more than 15 research consultants and almost 100<br />
research and information professionals.<br />
Our cus<strong>to</strong>mers mirror our worldwide nature. Around 45% are in Europe, 30% in the Americas, 13% in Asia<br />
Pacific and 12% in the Middle East and Africa.<br />
Our firm is intended <strong>to</strong> work as one. We are a solitary global research organization united <strong>by</strong> a solid<br />
arrangement of qualities, concentrated on cus<strong>to</strong>mer effect.
What we do<br />
We serve cus<strong>to</strong>mers at each level of their organization, in whatever limit we can be most helpful, whether<br />
as a trusted counsel <strong>to</strong> <strong>to</strong>p management or as a hands-on men<strong>to</strong>r for forefront representatives. For each<br />
engagement, we collect a group with the most suitable experience and ability.<br />
No matter the challenge, we concentrate on delivering functional and persevering results, and preparing<br />
our cus<strong>to</strong>mers <strong>to</strong> develop and lead. We join forces with cus<strong>to</strong>mers <strong>to</strong> place suggestions in<strong>to</strong> practice. Our<br />
research specialist work straightforwardly with cus<strong>to</strong>mers over long stretches <strong>to</strong> create workforce<br />
aptitudes, drive operational change, and apply new working strategies.<br />
Media Contact<br />
Name: Chris Smith (<strong>Global</strong> Sales Manager)<br />
Address: 105 N 1st ST #429, SAN JOSE, CA 95103 US<br />
E-mail: sales@credenceresearch.com<br />
Ph: 1-800-361-8290<br />
Web: http://www.credenceresearch.com